TheraRadar
Data updated: May 26, 2026

DRONEDARONE HYDROCHLORIDE

Trial Activity: Mature 1 active trials
Cardiovascular Approved 2024-01-31

Development Insights

Sanofi conducting 7 trials (64%)
2 indications explored (Focused)
atrial fibrillation (10 trials)
atrial fibrillation (af) (1 trials)
1
Indication
--
Phase 3 Trials
2
Years on Market

Details

Status
Discontinued
First Approved
2024-01-31
Routes
ORAL
Dosage Forms
TABLET

DRONEDARONE HYDROCHLORIDE Approval History

2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2024 to 2024
Jan 2024 ORIGINAL
Update

What DRONEDARONE HYDROCHLORIDE Treats

1 FDA approvals

Originally approved for its first indication in 2024 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DRONEDARONE HYDROCHLORIDE FDA Label Details

Looking for the branded version?

MULTAQ

Full clinical data, patents, trials, and competitive landscape for dronedarone hydrochloride.

See MULTAQ

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment